Virginiamycin

Summary

Virginiamycin is a naturally produced streptogramin antibiotic complex derived from Streptomyces virginiae, consisting primarily of virginiamycin M1 and virginiamycin S1. It has been widely used as a growth promoter in livestock (poultry, swine, cattle) and as a feed additive antibiotic. It is related to the clinical streptogramin combination quinupristin/dalfopristin (Synercid), which was developed partly in response to concerns that virginiamycin use in agriculture could select for streptogramin resistance in enterococci, complicating human treatment options.

Mechanism of Action

Virginiamycin is a mixture of two synergistic components: virginiamycin M1 (type A streptogramin, polyunsaturated macrolactone) and virginiamycin S1 (type B streptogramin, cyclic hexadepsipeptide). Together they inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit at two distinct sites, blocking peptide chain elongation and causing premature termination. The combination is bactericidal and synergistic.

Routes of Administration

Goals & Uses

• Gram-positive bacterial infection treatmentAntimicrobialLow
• Prevention of necrotic enteritis in poultryVeterinary / Infectious DiseaseModerate
• Growth promotion in livestockVeterinary / AgriculturalHigh

Contraindications

• Known hypersensitivity to streptograminsAllergyHigh
• Human therapeutic useRegulatory/safetyHigh

Adverse Effects

• Residue accumulation in food productsFood SafetyUnknown
• Selection for streptogramin-resistant enterococci (VRE)Antimicrobial ResistanceUnknown
• Gastrointestinal upset (in treated animals)GastrointestinalUncommon

Drug Interactions

• Quinupristin/dalfopristin (Synercid)High

Population Constraints

• Humans (general)Regulatory / SafetyAbsolute
• EU livestockGeographic / RegulatoryAbsolute
• Organic-certified livestock operationsAgricultural RegulatoryAbsolute

Regulatory Status

• European UnionWithdrawnBanned as a feed additive growth promoter in 1999 by the European Union due to concerns about antimicrobial resistance cross-selection with clinically important streptogramins.
• United StatesApprovedApproved: Growth promotion in poultry, Growth promotion in swine, Feed efficiency improvement in cattle, Prevention of necrotic enteritis in poultryApproved as a veterinary feed additive under FDA; sold under brand name Stafac. Not approved for human therapeutic use.
• United KingdomWithdrawnFollows EU ban implemented prior to Brexit; not approved as a growth promoter.

Approved in the United States as a veterinary feed additive for growth promotion and feed efficiency in poultry, swine, and cattle (FDA). The EU banned virginiamycin as a growth promoter in feed in 1999 due to concerns over cross-resistance with quinupristin/dalfopristin used clinically in humans. Not approved for human therapeutic use. Ongoing controversy regarding contribution to antimicrobial resistance.

Evidence & Sources

No sources recorded yet.